IPO rush on Wall Street: Uber’s former Chinese rival and Johnson & Johnson-backed co to list next

By: |
June 25, 2021 2:27 PM

The IPO rush on Wall Street has been going strong so far in 2021 and has no intentions of slowing down.

ipoThe initial public offering (IPO) is purely an offer of sale for 1,36,69,478 equity shares by promoters and an existing shareholder, according to the draft red herring prospectus (DRHP).

The IPO rush on Wall Street has been going strong so far in 2021 and has no intentions of slowing down. As the US economy unlocks and the vaccinated population continues to grow, a large number of companies from across the globe are eying listing their stocks on Wall Street, adding to the already 550 initial public offerings seen by investors. The number has already surpassed the record figure of 480 IPOs seen last year. The public offerings are, however, not slowing down anytime soon. Here are some of the hot upcoming IPOs on Wall Street.

Didi Chuxing

Chinese ride-hailing application is set to make its NYSE debut in the coming days. According to its filing with US Securities and Exchange Commission (SEC), 288 million American Depositary Shares of Didi will list at a price of $13-14 per share. With this the company will raise $4 billion, making it one of the largest IPOs seen by US investors in recent years. The stocks of Didi could list as soon as next Wednesday on the New York Stock Exchange. The company is aiming for a valuation of $60 billion, according to Reuters. Four ADSs represent one Class A ordinary share.

The company has been operating in China and once faced competition from Uber, before the latter exited China. Didi operates in 16 countries or nearly 4,000 cities with 493 active users annually. The company plans to use the raised amount to invest in their technology capabilities including our shared mobility, electric vehicle, and autonomous driving technologies. Funds will also be used to grow in international markets.


Medical device maker CVRx could also list on the stock exchanges soon. Recent filings with the SEC show that CVRx is offering investors 6,250,000 common stock in the price band of $15 to $17 per share to list on the NASDAQ index. “We estimate that the net proceeds from the sale of 6,250,000 shares of common stock in this offering will be approximately $91.5 million at an assumed initial public offering price of $16.00 per share,” the filing read. The amount could increase to $105 million if underwriters exercise their option to purchase additional shares in full. The company plans to use the raised funds for the expansion of our direct sales force and commercial organization

CVRx markets BAROSTIM NEO, a medical device for heart failure and resistant hypertension. The company is supported by leading medical technology investors including Johnson & Johnson. A subsidiary of Johnson & Johnson Innovation holds a 31.8% stake in the company pre-issue which will fall to 21.4% post issue.

Looking to invest in US Stocks? Open a free account with Stockal - India's first borderless investment platform.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Cybersecurity ETFs to consider amidst increasing threat from Internet crimes
2Stocks rise as U.S. growth outweighs cautious mood
3US Stocks rise amid gains in cyclicals while technology stocks fall